PRALYBRI CARBETOCIN Trademark

Trademark Overview

On Wednesday, November 3, 2021, a trademark application was filed for PRALYBRI CARBETOCIN with the United States Patent and Trademark Office. The USPTO has given the PRALYBRI CARBETOCIN trademark a serial number of 97107395. The federal status of this trademark filing is FOURTH EXTENSION - GRANTED as of Monday, March 18, 2024. This trademark is owned by Levo Therapeutics, Inc.. The PRALYBRI CARBETOCIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products and preparations made in significant part of carbetocin for the treatment of Prader-Willi syndrome (PWS) and related disorders; pharmaceutical products and preparations made in significant part of carbetocin for the treatment of neurodevelopmental and metabolic disorders
pralybri carbetocin

General Information

Serial Number97107395
Word MarkPRALYBRI CARBETOCIN
Filing DateWednesday, November 3, 2021
Status733 - FOURTH EXTENSION - GRANTED
Status DateMonday, March 18, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, February 15, 2022

Trademark Statements

Description of MarkThe mark consists of the word "PRALYBRI" in stylized, lowercase letters. To the lower right of "PRALYBRI" is the word "CARBETOCIN" in stylized, lowercase letters. To the upper right of "PRALYBRI" is a design of a flower.
Goods and ServicesPharmaceutical products and preparations made in significant part of carbetocin for the treatment of Prader-Willi syndrome (PWS) and related disorders; pharmaceutical products and preparations made in significant part of carbetocin for the treatment of neurodevelopmental and metabolic disorders
Disclaimer with Predetermined Text"CARBETOCIN"

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, November 15, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameLevo Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSkokie, IL 60077
Party NameLevo Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSkokie, IL 60077

Trademark Events

Event DateEvent Description
Tuesday, March 19, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, March 18, 2024SOU EXTENSION 4 GRANTED
Monday, March 18, 2024SOU EXTENSION 4 FILED
Monday, March 18, 2024SOU TEAS EXTENSION RECEIVED
Friday, September 22, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 20, 2023SOU EXTENSION 3 GRANTED
Wednesday, September 20, 2023SOU EXTENSION 3 FILED
Wednesday, September 20, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, March 21, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, March 17, 2023SOU EXTENSION 2 GRANTED
Friday, March 17, 2023SOU EXTENSION 2 FILED
Friday, March 17, 2023SOU TEAS EXTENSION RECEIVED
Monday, November 28, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, November 28, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, November 28, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, September 16, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, September 14, 2022SOU EXTENSION 1 GRANTED
Wednesday, September 14, 2022SOU EXTENSION 1 FILED
Wednesday, September 14, 2022SOU TEAS EXTENSION RECEIVED
Tuesday, April 12, 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, February 15, 2022OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 15, 2022PUBLISHED FOR OPPOSITION
Wednesday, January 26, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Wednesday, January 12, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 12, 2022EXAMINER'S AMENDMENT ENTERED
Wednesday, January 12, 2022NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, January 12, 2022EXAMINERS AMENDMENT E-MAILED
Wednesday, January 12, 2022EXAMINERS AMENDMENT -WRITTEN
Wednesday, January 5, 2022PREVIOUS ALLOWANCE COUNT WITHDRAWN
Tuesday, December 14, 2021WITHDRAWN FROM PUB - OG REVIEW QUERY
Wednesday, December 1, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 1, 2021EXAMINER'S AMENDMENT ENTERED
Wednesday, December 1, 2021NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Wednesday, December 1, 2021EXAMINERS AMENDMENT E-MAILED
Wednesday, December 1, 2021EXAMINERS AMENDMENT -WRITTEN
Sunday, November 28, 2021NOTIFICATION OF NON-FINAL ACTION E-MAILED
Sunday, November 28, 2021NON-FINAL ACTION E-MAILED
Sunday, November 28, 2021NON-FINAL ACTION WRITTEN
Tuesday, November 23, 2021ASSIGNED TO EXAMINER
Tuesday, November 16, 2021NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, November 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, November 6, 2021NEW APPLICATION ENTERED

Related Keywords

carbetocin pralybri pharmaceutical disorders part treatment significant products preparations made neurodevelopmental